1. Home
  2. ALXO vs BRFH Comparison

ALXO vs BRFH Comparison

Compare ALXO & BRFH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ALXO
  • BRFH
  • Stock Information
  • Founded
  • ALXO 2015
  • BRFH 2005
  • Country
  • ALXO United States
  • BRFH United States
  • Employees
  • ALXO N/A
  • BRFH N/A
  • Industry
  • ALXO Biotechnology: Pharmaceutical Preparations
  • BRFH Packaged Foods
  • Sector
  • ALXO Health Care
  • BRFH Consumer Staples
  • Exchange
  • ALXO Nasdaq
  • BRFH Nasdaq
  • Market Cap
  • ALXO 56.8M
  • BRFH 46.2M
  • IPO Year
  • ALXO 2020
  • BRFH N/A
  • Fundamental
  • Price
  • ALXO $1.05
  • BRFH $2.86
  • Analyst Decision
  • ALXO Strong Buy
  • BRFH
  • Analyst Count
  • ALXO 6
  • BRFH 0
  • Target Price
  • ALXO $3.30
  • BRFH N/A
  • AVG Volume (30 Days)
  • ALXO 1.7M
  • BRFH 5.1K
  • Earning Date
  • ALXO 11-06-2025
  • BRFH 10-23-2025
  • Dividend Yield
  • ALXO N/A
  • BRFH N/A
  • EPS Growth
  • ALXO N/A
  • BRFH N/A
  • EPS
  • ALXO N/A
  • BRFH N/A
  • Revenue
  • ALXO N/A
  • BRFH $10,979,000.00
  • Revenue This Year
  • ALXO N/A
  • BRFH $23.09
  • Revenue Next Year
  • ALXO N/A
  • BRFH $41.03
  • P/E Ratio
  • ALXO N/A
  • BRFH N/A
  • Revenue Growth
  • ALXO N/A
  • BRFH 24.51
  • 52 Week Low
  • ALXO $0.40
  • BRFH $1.81
  • 52 Week High
  • ALXO $2.36
  • BRFH $4.60
  • Technical
  • Relative Strength Index (RSI)
  • ALXO 54.14
  • BRFH 45.86
  • Support Level
  • ALXO $1.01
  • BRFH $2.84
  • Resistance Level
  • ALXO $1.27
  • BRFH $3.10
  • Average True Range (ATR)
  • ALXO 0.12
  • BRFH 0.14
  • MACD
  • ALXO -0.02
  • BRFH -0.01
  • Stochastic Oscillator
  • ALXO 29.03
  • BRFH 5.88

About ALXO ALX Oncology Holdings Inc.

ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. The company is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches.

About BRFH Barfresh Food Group Inc.

Barfresh Food Group Inc develops, manufactures and distributes ready to blend frozen beverages, including smoothies, shakes and frappes for restaurant chains and the foodservice industry. The company's proprietary, patented system uses portion-controlled pre-packaged beverage ingredients that deliver freshly made frozen beverages that are quick, cost efficient, and without waste. Barfresh provides both a single serve solution and a bulk format solution, ideal for high-volume locations. It has seven flavors available as part of its standard line vanilla shake, caribbean smoothie, triple berry smoothie, caramel macchiato frappe, strawberry banana smoothie, mocha frappe and mango burst smoothie and has the development capabilities to deliver custom flavors.

Share on Social Networks: